Bevacizumab Ups Progression-Free Survival in Ovarian Cancer

Share this content:
Bevacizumab Ups Progression-Free Survival in Ovarian Cancer
Bevacizumab Ups Progression-Free Survival in Ovarian Cancer

HealthDay News – For women with ovarian cancer, the addition of bevacizumab to standard chemotherapy results in significantly improved progression-free survival (PFS), according to two Phase 3 studies published in the December 29 issue of the New England Journal of Medicine.

Robert A. Burger, MD, from the Fox Chase Cancer Center in Philadelphia, and colleagues evaluated the addition of bevacizumab to standard front-line therapy for 1,873 women with stage III or IV epithelial ovarian cancer. The participants were randomly allocated to receive paclitaxel plus carboplatin (control group), bevacizumab-initiation treatment, or bevacizumab-throughout treatment. PFS was the primary end point. The median PFS in the control, bevacizumab-initiation, and bevacizuman-throughout groups was 10.3, 11.2, and 14.1 months, respectively. The hazard ratio (HR) for progression to death was 0.908 for the bevacizumab-initiation group (95% confidence interval [CI], 0.795–1.040) and 0.717 (95% CI, 0.625–0.824) for the bevacizumab-throughout group.

Timothy J. Perren, MD, from St. James's University Hospital in Leeds, U.K., and colleagues investigated the effect of bevacizumab on survival in 1,528 women from 11 countries with ovarian cancer (90% with epithelial ovarian cancer; 70% with stage IIIC or IV cancer). The participants were randomly allocated to receive carboplatin and paclitaxel (standard therapy) or standard therapy plus bevacizumab. PFS at 36 months was significantly longer for standard therapy plus bevacizumab (21.8 vs. 20.3 months; HR for progression or death with adjuvant bevacizumab, 0.81). In an updated analysis at 42 months, PFS was significantly longer with bevacizumab (24.1 vs. 22.4 months).

"Bevacizumab improved progression-free survival in women with ovarian cancer," Perren and colleagues write.

Burger's study was partially funded by Genentech; Perren's study was partially funded by Roche, both of which manufacture bevacizumab.

Full Text - Burger (subscription or payment may be required)
Full Text - Perren (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs